Sort
50,496 grants matching “lung cancer”
Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy
$1,482,455Fadlo Raja Khuri · Emory University · P01 · FY2007 · CA
A resource for magnetic resonance and optical imaging
$1,481,535Ravinder Reddy · University Of Pennsylvania · P41 · FY2013 · EB
Towards a Comprehensive, Spatiotemporal Roadmap of Cancer Metastasis
$1,480,500Dian Yang · Columbia University Health Sciences · DP2 · FY2024 · CA
Activities Of Chemokines In Health and Disease
$1,480,285Joshua M Farber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
$1,480,200Mitchell Machtay · Case Western Reserve University · UG1 · FY2019 · CA
Chemokines in Skin Immune Cell Trafficking & Cancer Progression
$1,480,101Sam Hwang · Clinical Sciences · Z01 · FY2007 · CA
MULTIETHNIC/MINORITY COHORT STUDY OF DIET AND CANCER
$1,479,406University Of Hawaii At Manoa · R01 · FY2000 · CA
Southwest Environmental Health Sciences Center
$1,478,854Serrine S Lau · University Of Arizona · P30 · FY2010 · ES
DEVELOPMENT OF NOVEL ANTICANCER AGENT TO POTENTIATE SENSITIVITY TO ANTI-ESTROGEN THERAPY
$1,478,552Ginette Serrero · A And G Pharmaceutical, Inc. · N44 · FY2014 · CA
Preclinical Core
$1,478,239Jeffrey T Yap · University Of Utah · U54 · FY2018 · CA
Deciphering microbial virulence mechanisms during Legionella pneumophila infection
$1,477,613Matthias Machner · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2019 · HD
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL - SCREEN
$1,477,597Timothy Church · · N01 · FY2007 · CA
Strategies for Cancer Immunotherapy Development: Preclinical Studies
$1,477,304Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Research Capacity Core
$1,476,352Yanyuan Wu · Charles R. Drew University Of Med & Sci · U54 · FY2025 · MD
TOWARDS A MOLECULAR CLASSIFICATION OF TUMORS
$1,476,272University Of Michigan At Ann Arbor · U19 · FY2001 · CA
IGF::OT::IGF: SBIR Phase II, Topic 326: Development of Novel Therapeutic Agents that Target Cancer
$1,475,002Rajappa Kenchappa · Transgenex Nanobiotech, Inc. · N44 · FY2017 · CA
ACOSOG Community Clinical Oncology Program (CCOP) Research Base
$1,474,780Jeff Sloan Sloan · Mayo Clinic Rochester · U10 · FY2012 · CA
THE IMMUNOMODULATORY IMPACT OF CHEMOTHERAPY WHEN COMBINED WITH PD-1 BLOCKADE IN RESECTABLE LUNG CANCER
$1,473,750The Johns Hopkins University · · FY2025 · Defense Health Agency
Developmental Funds
$1,473,039Susan M Domchek · University Of Pennsylvania · P30 · FY2024 · CA
Control of Oncogenic Signaling Through Spatial Organization of Kinases and mRNAs
$1,472,076Peter F Johnson · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
TNF Signaling, Cell Death and Cancer
$1,471,899Zheng-Gang Liu · Division Of Clinical Sciences - Nci · ZIA · FY2021 · CA
Cancer Epidemiology Cohort in Male Health Professionals
$1,471,244Lorelei Mucci · Harvard University D/B/A Harvard School Of Public Health · U01 · FY2025 · CA
PLCO Trial Etiologic and Early Marker Study
$1,470,351Neal Freedman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2020 · CA
Cancer Epidemiology Cohort in Male Health Professionals
$1,469,906Walter C. Willett · Harvard School Of Public Health · U01 · FY2022 · CA
OCCUPATIONAL AND ENVIRONMENTAL HEALTH
$1,469,795Harvard University (Sch Of Public Hlth) · P30 · FY2002 · ES